UO

UBS Oncology Impact Fund

Europe, Zurich, Switzerland, Zürich

Description

UBS Oncology Impact Fund

Investor Profile

UBS Oncology Impact Fund has backed more than 5 startups, with 0 new investments in the last 12 months alone. The firm has led 1 rounds, about 20% of its total and boasts 3 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series A, Series B rounds (top funding stages).
  • Majority of deals are located in United States, Canada.
  • Strong thematic focus on Biotechnology, Oncology, Therapeutics.

Stage Focus

  • Series A (60%)
  • Series B (40%)

Country Focus

  • United States (60%)
  • Canada (40%)

Industry Focus

  • Biotechnology
  • Oncology
  • Therapeutics
  • Health Care
  • Pharmaceutical
  • Medical
  • Alternative Medicine
  • Information Technology
  • Biopharma
  • Medical Device
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does UBS Oncology Impact Fund frequently co-invest with?

Fonds de solidarité FTQ
North America, Quebec, Canada, Montréal
Co-Investments: 2
MPM Capital
North America, Massachusetts, United States, Boston
Co-Investments: 4
Versant Ventures
North America, California, United States, Menlo Park
Co-Investments: 2
Celgene
North America, New Jersey, United States, Summit
Co-Investments: 2
IMM Investment
Asia, Cholla-namdo, South Korea, Kangnam
Co-Investments: 1
CH
North America, New York, United States, New York
Co-Investments: 2
Deerfield
North America, New York, United States, New York
Co-Investments: 1
Astellas Venture Management
North America, California, United States, Menlo Park
Co-Investments: 1
AB
Asia, Tel Aviv, Israel, Herzliya
Co-Investments: 1
Redmile Group
North America, California, United States, San Francisco
Co-Investments: 2

Which angels does UBS Oncology Impact Fund often collaborate with?

SB
Europe, England, United Kingdom, London
Shared Deals: 1

What are some of recent deals done by UBS Oncology Impact Fund?

Repare Therapeutics

Saint Laurent, Quebec, Canada

Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells.

BiotechnologyHealth CareOncologyPharmaceuticalTherapeutics
Series BSep 4, 2019
Amount Raised: $82,500,000
Oncorus

Cambridge, Massachusetts, United States

Oncorus is an immuno-oncology company developing oncolytic viruses to fight cancer.

BiotechnologyMedicalOncologyTherapeutics
Series BAug 21, 2019
Amount Raised: $79,500,000
ElevateBio

Waltham, Massachusetts, United States

ElevateBio is a biotechnology company that specializes in cell and gene-based therapies.

Alternative MedicineBiotechnologyInformation Technology
Series AMay 13, 2019
Amount Raised: $150,000,000
Cullinan Therapeutics

Cambridge, Massachusetts, United States

Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics used to end a drug program quickly.

BiopharmaBiotechnologyMedical DeviceOncology
Series AOct 3, 2017
Amount Raised: $150,000,000
Repare Therapeutics

Saint Laurent, Quebec, Canada

Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells.

BiotechnologyHealth CareOncologyPharmaceuticalTherapeutics
Series AJun 22, 2017
Amount Raised: $68,000,000

Find More Investors Like UBS Oncology Impact Fund

Discover similar investors in our database and build your perfect investor list.

Need help with your fundraising strategy?Read our fundraising guides

UBS Oncology Impact Fund | Pipeseed